Skip to content
HowShorted

Zentalis Pharmaceuticals, Inc. short interest in 2022

In 2022, Zentalis Pharmaceuticals, Inc.'s disclosed short interest ran from 6.94% of shares outstanding on 14 Jan 2022 to 11.16% on 30 Dec 2022, a change of +4.22 percentage points. The year's high was 15.13% on 30 Jun 2022 and its low 6.94% on 14 Jan 2022, averaging 10.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.75 days on 30 Nov 2022. Full history: Zentalis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Zentalis Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
6.94% (14 Jan 2022)
End of year
11.16% (30 Dec 2022)
Change
+4.22 pp
High
15.13% (30 Jun 2022)
Low
6.94% (14 Jan 2022)
Average
10.54%
Highest days to cover
16.75 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

Zentalis Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.94%11.68
31 Jan 20227.02%9.57
15 Feb 20228.04%12.53
28 Feb 20228.64%10.5510-K filed, results (8-K)
15 Mar 20228.88%11.00
31 Mar 202210.59%10.83
14 Apr 202210.63%3.80
29 Apr 20229.54%5.12
13 May 202210.10%6.1810-Q filed, results (8-K)
31 May 202211.50%4.40
15 Jun 202213.45%10.67
30 Jun 202215.13%8.12
15 Jul 202214.62%10.03
29 Jul 202213.54%15.02
15 Aug 202210.22%7.6110-Q filed, results (8-K)
31 Aug 202210.61%10.57
15 Sep 202210.66%7.75
30 Sep 202210.53%9.11
14 Oct 202210.31%11.06
31 Oct 202210.46%15.42
15 Nov 202210.13%7.1110-Q filed, results (8-K)
30 Nov 202210.60%16.75
15 Dec 20229.75%12.50
30 Dec 202211.16%12.18

See also: Zentalis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.